[Quantification of Ki-67 in PitNET (pituitary Neuroendocrine Tumors)/adenomas]

Overview

Journal Pathologie (Heidelb)

Specialty Pathology

Date 2024 Jul 11

PMID 38992316

Authors

Judith Klein

Kai Saeger

Wolfgang Saeger

Affiliations

Soon will be listed here.

Abstract

This study is the first to compare the determination of the Ki-67 index in pituitary neuroendocrine tumors (PitNET)/pituitary adenomas by pathologists with a computerized method (Cognition MasterSuite from VMScope, Berlin, Germany). PitNET/pituitary adenomas often show a low proliferation index. Observer variability is high, especially when estimating in this low percentage range. A more reliable determination would be possible using the four-eyes principle, but this cannot be realized continuously; thus, digital image analysis is a promising solution. In the study, there was clear agreement between the Ki-67 estimate by two experienced pathologists and the determination with the aid of digital image analysis. The digital image analysis system is excellent for determining the proliferation rate of PitNET/pituitary adenomas and can therefore be used to determine the "third" and "fourth eye".

Citing Articles

Radiological and Immunohistochemical Characteristics of PitNETs in 79 Patients Undergoing Neurosurgery.

Krzentowska A, Czepko R, Adamek D, Filipowicz M, Broniatowska E, Golkowski F Cancers (Basel). 2025; 17(4).

PMID: 40002261 PMC: 11852720. DOI: 10.3390/cancers17040666.

References

Liu J, He Y, Zhang X, Yan X, Huang Y . Clinicopathological analysis of 250 cases of pituitary adenoma under the new WHO classification. Oncol Lett. 2020; 19(3):1890-1898. PMC: 7039149. DOI: 10.3892/ol.2020.11263. View

Petry C, Poli J, de Azevedo Dossin I, Garcia Soares Leaes Rech C, Lima J, Ferreira N . Evaluation of the potential of the Ki67 index to predict tumor evolution in patients with pituitary adenoma. Int J Clin Exp Pathol. 2020; 12(1):320-326. PMC: 6944029. View

Jaursch-Hancke C, Deutschbein T, Knappe U, Saeger W, Flitsch J, Fassnacht M . The Interdisciplinary Management of Newly Diagnosed Pituitary Tumors. Dtsch Arztebl Int. 2021; 118(14):237-243. PMC: 8283682. DOI: 10.3238/arztebl.m2021.0015. View

Klauschen F, Wienert S, Schmitt W, Loibl S, Gerber B, Blohmer J . Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study. Clin Cancer Res. 2014; 21(16):3651-7. DOI: 10.1158/1078-0432.CCR-14-1283. View

Zaidi H, Cote D, Dunn I, Laws Jr E . Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas. J Clin Neurosci. 2016; 34:246-251. DOI: 10.1016/j.jocn.2016.09.014. View

Melmed S, Kaiser U, Lopes M, Bertherat J, Syro L, Raverot G . Clinical Biology of the Pituitary Adenoma. Endocr Rev. 2022; 43(6):1003-1037. PMC: 9695123. DOI: 10.1210/endrev/bnac010. View

Miermeister C, Petersenn S, Buchfelder M, Fahlbusch R, Ludecke D, Holsken A . Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications. Acta Neuropathol Commun. 2015; 3:50. PMC: 4545559. DOI: 10.1186/s40478-015-0229-8. View

Hacking S, Sajjan S, Lee L, Ziemba Y, Angert M, Yang Y . Potential Pitfalls in Diagnostic Digital Image Analysis: Experience with Ki-67 and PHH3 in Gastrointestinal Neuroendocrine Tumors. Pathol Res Pract. 2019; 216(3):152753. DOI: 10.1016/j.prp.2019.152753. View

Chiloiro S, Bianchi A, Doglietto F, de Waure C, Giampietro A, Fusco A . Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review. Pituitary. 2013; 17(3):267-76. DOI: 10.1007/s11102-013-0500-6. View

10.

Lelotte J, Mourin A, Fomekong E, Michotte A, Raftopoulos C, Maiter D . Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients. Eur J Endocrinol. 2017; 178(3):237-246. DOI: 10.1530/EJE-17-0965. View

11.

Sadeghipour A, Mahouzi L, Salem M, Ebrahim-Nejad S, Asadi-Lari M, Radfar A . Ki67 Labeling Correlated With Invasion But Not With Recurrence. Appl Immunohistochem Mol Morphol. 2016; 25(5):341-345. DOI: 10.1097/PAI.0000000000000303. View

12.

Koch R, Sporl E . [Statistical methods for comparison of two measuring procedures and for calibration: analysis of concordance, correlation and regression in the case of measuring intraocular pressure]. Klin Monbl Augenheilkd. 2007; 224(1):52-7. DOI: 10.1055/s-2006-927278. View

13.

Hadzhiyanev A, Ivanova R, Nachev E, Elenkova A, Yaneva M, Zaharieva S . Evaluation of prognostic utility of MIB-1 and p53 expression in pituitary adenomas: correlations with clinical behaviour and follow-up results. Biotechnol Biotechnol Equip. 2015; 28(3):502-507. PMC: 4433927. DOI: 10.1080/13102818.2014.932510. View

14.

Polley M, Leung S, McShane L, Gao D, Hugh J, Mastropasqua M . An international Ki67 reproducibility study. J Natl Cancer Inst. 2013; 105(24):1897-906. PMC: 3888090. DOI: 10.1093/jnci/djt306. View

15.

Volynskaya Z, Mete O, Pakbaz S, Al-Ghamdi D, Asa S . Ki67 Quantitative Interpretation: Insights using Image Analysis. J Pathol Inform. 2019; 10:8. PMC: 6437785. DOI: 10.4103/jpi.jpi_76_18. View

16.

Raverot G, Ilie M, Lasolle H, Amodru V, Trouillas J, Castinetti F . Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol. 2021; 17(11):671-684. DOI: 10.1038/s41574-021-00550-w. View

17.

Buurman H, Saeger W . Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol. 2006; 154(5):753-8. DOI: 10.1530/eje.1.02107. View